As part of my review I took the time to reread the presentation...

As part of my review I took the time to reread the presentation from the 2010 meeting. A couple of aspects really stood out:
- "We expect that Lilly will launch Axiron into the US market in the first half of 2011 and proceed to file marketing applications for Axiron in a number
of countries outside of the US.
- with regards to our global veterinary health partnership, Elanco is anticipating a decision from the FDA in Q1 2011 in relation to their first animal health product and if approved this could be available in the US by mid-2011.
- we are expecting a decision from the Swedish MPA in relation to our Ellavie product during Q1 2011 and shortly following this we will look to secure a suitable distributor for the major European markets."

So regarding Axiron and potential for income over the next 2yrs , it is probably well mapped out.
The further comments from our CEO regarding the longer term strategies are interesting:

"I should emphasise that we are fully committed to extracting maximum value from all
commercially relevant applications of our platform technology, however it is reasonable
to assume that the value-add, on a scale of what we have managed to achieve with
Axiron, is more likely at this stage of our company?s development, to come from
externally sourced opportunities.
With this in mind, the Acrux Board is evaluating all growth opportunities that may be
complimentary or synergistic to our existing business. We have a strong financial
position, a committed Board and management team and some very significant
partnerships in place. The Board intends to maintain a disciplined approach to
evaluating any such opportunities and will ensure that shareholders funds are deployed
in a productive way with the commensurate level of returns."